News

Update on Adrabetadex - Dr. Steve Romano, Mallinckrodt’s Executive Vice President and Chief Scientific Officer

The following is an update on Adrabetadex from Dr. Steve Romano, Mallinckrodt’s Executive Vice President and Chief Scientific Officer...

Cyclo Therapeutics Closes $2.8 Million Private Placement Led by Novit LP with $1.0 Million

GAINESVILLE, FL – (BusinessWire) – August 27, 2020 – Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that it has closed a private placement of its securities with a group of accredited investors...

Digital Annual Family Conference & Interactive Workshop 2020 (REGISTER NOW!)

We are excited to announce that registration for our very first Digital Annual Family Conference & Interactive Workshop on Niemann-Pick Disease, is now open!

Orphazyme completes rolling submission of New Drug Application to U.S. FDA for arimoclomol for Niemann-Pick disease Type C

Mallinckrodt Pharmaceuticals Statement: Adrabetadex for NPC-1

Please take a moment to read this important announcement from Mallinckrodt Pharmaceuticals in regard to the clinical trial of Adrabetadex for NPC-1. We recognise that this may be a surprising and disappointing development for our community as a whole. Please be assured that we are advocating for further, clearer information and will follow up with our response and next steps shortly.

Sandra Cowie, President, INPDA
Joslyn Crowe, Executive Director, NNPDF
Toni Mathieson, Chief Executive, NPUK